Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Trial Updates

Clinical trials play an important role in providing patients with access to novel therapeutic agents, and options after standard of care treatment approaches fail. Discover the latest updates from clinical trials being conducted in several disease areas, including multiple myeloma, CLL, ALL, AML, and lymphoma.

Multiple Myeloma

View all
Efficacy and safety of GPRC5D-targeted QLS32015 in multiple myeloma 2:49
Efficacy and safety of GPRC5D-targeted QLS32015 in multiple myeloma
Jian Cui • 23 Sep 2026
Ramantamig safety and efficacy in relapsed/refractory multiple myeloma 1:35
Ramantamig safety and efficacy in relapsed/refractory multiple myeloma
Jeffrey Matous • 25 Sep 2026

CLL

View all
Insights into the current CLL treatment algorithm and emerging research directions 1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL 4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026

AML

View all
Novel targets, combinations, and treatments in AML: insights from iwAL 2026 19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML 10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026

ALL

View all
Reshaping frontline Ph+ ALL: third-generation TKI plus immunotherapy 2:04
Reshaping frontline Ph+ ALL: third-generation TKI plus immunotherapy
Josep-Maria Ribera • 14 Sep 2026
Insights from the AIEOP-BFM ALL trial: could blinatumomab replace high-dose chemotherapy in HR ALL? 1:48
Insights from the AIEOP-BFM ALL trial: could blinatumomab replace high-dose chemotherapy in HR ALL?
Martin Schrappe • 11 Jun 2026

Lymphoma

View all
Using prognostic and molecular markers to guide frontline therapy in mantle cell lymphoma 2:35
Using prognostic and molecular markers to guide frontline therapy in mantle cell lymphoma
Jonathon Cohen • 10 Sep 2026
Evolving treatment strategies at first relapse in follicular lymphoma 1:08
Evolving treatment strategies at first relapse in follicular lymphoma
Bradley Hunter • 21 Sep 2026

Non-Malignant

View all
Nipocalimab shows pharmacodynamic activity in warm autoimmune hemolytic anemia 2:40
Nipocalimab shows pharmacodynamic activity in warm autoimmune hemolytic anemia
Yasutaka Ueda • 13 Jun 2026
3-year COMMODORE-1 data support long-term crovalimab in PNH 1:28
3-year COMMODORE-1 data support long-term crovalimab in PNH
Yasutaka Ueda • 13 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals